The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta‐analysis

Liu, Xiangqi; Chen, Dongru; Lao, Xiaomei; Liang, Yujie

doi:10.1002/hed.25597

Cited by 17 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is partly contradicting information in the literature whether the MYB fusion carries prognostic information. Although some studies have suggested certain correlations between MYB alterations and various clinicopathological parameters, most have failed to find significant associations [ 21 , 36 ]. For instance, Rettig et al [ 28 ] have suggested that minor salivary gland ACCs are more often MYB fusion-positive and that fusions are more common in females than in males.…”

Section: Discussionmentioning

confidence: 99%

Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study

Persson

Andersson

Mitani

et al. 2022

Cancers

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC) is an aggressive head and neck malignancy characterized by a t (6;9) translocation resulting in an MYB–NFIB gene fusion or, more rarely, an MYBL1 fusion. The true frequency and clinical significance of these alterations are still unclear. Here, we have used tissue microarrays and analyzed 391 ACCs and 647 non-ACC salivary neoplasms to study the prevalence, expression, and clinical significance of MYB/MYBL1 alterations by FISH and immunohistochemistry. Alterations of MYB or MYBL1 were found in 78% of the cases, of which 62% had MYB alterations and 16% had MYBL1 rearrangements. Overexpression of MYB/MYBL1 oncoproteins was detected in 93% of the cases. MYB split signal, seen in 39% of the cases, was specific for ACC and not encountered in non-ACC salivary tumors. Loss of the 3′-part of MYB was enriched in grade 3 tumors and was a significant independent prognostic biomarker for overall survival in multivariate analyses. We hypothesize that loss of the 3′-part of MYB results from an unbalanced t(6;9) leading to an MYB–NFIB fusion with concomitant loss of the segment distal to the MYB breakpoint in 6q23.3. Our study provides new knowledge about the prevalence and clinical significance of MYB/MYBL1 alterations and indicates the presence of genes with tumor suppressive functions in 6q23.3-qter that contribute to poor prognosis and short overall survival in ACC.

show abstract

Section: Discussionmentioning

confidence: 99%

Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study

Persson

Andersson

Mitani

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The MYB transcription factor can regulate diverse signaling pathways to control the differentiation, survival, and growth of cells such that it is a key mediator of tumorigenesis in many cancer types [ 28 – 30 ]. Liu et al found that SACC tumor tissues exhibit MYB overexpression which drives the proliferation and metastasis of these tumor cells such that it is a viable target for SACC treatment [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis

Xie

et al. 2021

Aging

View full text Add to dashboard Cite

The long non-coding RNA (lncRNA) SNHG3 has been shown to play oncogenic roles in several cancer types, but the mechanisms underlying its activity are poorly understood. In this study, we aimed to explore the clinical relevance and mechanistic role of SNHG3 in gastric cancer (GC). We found that SNHG3 expression in GC cell lines and tissues was significantly increased, and the upregulation of this lncRNA was correlated with tumor clinical stage and decreased patient survival. Knocking down SNHG3 in GC cells impaired the proliferative, migratory, and invasive activity in vitro and constrained in vivo GC xenograft tumor growth. Mechanistically, SNHG3 was found to bind and sequester miR-139-5p, thereby indirectly promoting the upregulation of the miR-139-5p target gene MYB. These data demonstrated that SNHG3 functions in an oncogenic manner to drive GC proliferation, migration, and invasion by regulating the miR-139-5p/MYB axis.

show abstract

“…It is important to note that the MYB protein is overexpressed in upwards of 80% of all ACC, suggesting a central role for MYB in ACC’s pathogenesis even in the absence of a MYB-NFIB fusion [ 25 ]. Contrary to initial studies, the cumulative evidence suggests that neither translocation nor overexpression of MYB carries meaningful prognostic significance in ACC [ 26 ].…”

Section: Biology Of Accmentioning

confidence: 91%

Approaches to the Management of Metastatic Adenoid Cystic Carcinoma

Lee

Wai

Chan

et al. 2022

Cancers

View full text Add to dashboard Cite

High rates of recurrence and distant metastasis are a foremost challenge in the management of adenoid cystic carcinoma (ACC), occurring in approximately 40% of all ACC patients. Despite the morbidity and mortality resulting from recurrent/metastatic (R/M) disease, there are no FDA-approved systemic agents for these patients. In this review, we summarize pertinent ACC pathophysiology and its implications for different systemic treatment regimens in R/M ACC. We review the evidence for the most widely used systemic agents — cytotoxic chemotherapy and tyrosine kinase inhibitors (TKIs) targeting VEGFR — in addition to immune checkpoint inhibitors and non-TKI biologic agents. Exciting emerging targets for R/M ACC, including inhibitors of Notch signaling, stemness, PRMT5, and Axl, are also discussed. Lastly, we review local therapies for small-volume lung disease in patients with oligometastatic ACC, specifically pulmonary metastasectomy and stereotactic body radiation therapy (SBRT). Future development of targeted molecular agents which exploit the underlying biology of this disease may yield novel therapeutic options to improve clinical outcomes in patients with R/M ACC.

show abstract

The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta‐analysis

Cited by 17 publications

References 35 publications

Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study

Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study

LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis

Approaches to the Management of Metastatic Adenoid Cystic Carcinoma

Contact Info

Product

Resources

About